NCT04716959

Brief Summary

The purpose of this study is to compare two standard techniques for breast reconstruction-the prepectoral technique and the subpectoral technique. Again, the prepectoral technique involves putting a tissue expander on top of the pectoralis muscle, while the subpectoral technique involves putting a tissue expander under the pectoralis muscle. The standard approach used at MSK is the subpectoral technique. This study will help researchers find out whether the subpectoral approach is better, the same as, or worse than the prepectoral approach. To decide which approach is better, the researchers will look at which technique causes fewer complications after surgery (for example, infection or the need for a second surgery). Researchers are also interested in seeing which approach causes less pain and use of pain medication after surgery.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2021

Shorter than P25 for phase_3

Geographic Reach
1 country

7 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 14, 2021

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

January 19, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 20, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 13, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 13, 2021

Completed
Last Updated

January 3, 2022

Status Verified

December 1, 2021

Enrollment Period

11 months

First QC Date

January 19, 2021

Last Update Submit

December 13, 2021

Conditions

Keywords

ProstheticBreast tissue expander20-565

Outcome Measures

Primary Outcomes (1)

  • major perioperative complications

    90-day major complications for tissue expanders (i.e., infection, explantation, and reoperation for mastectomy flap necrosis): * Infection: any event requiring restart of antibiotics (oral or intravenous) following completion of initial perioperative antibiotics or an admission to the hospital for cellulitis. * Explantation: need for tissue expander removal for any cause. * Reoperation: skin excision performed in either the clinic or the main operating room for mastectomy skin flap necrosis.

    90 days

Secondary Outcomes (1)

  • minor complications

    90 days

Study Arms (2)

Prepectoral Prosthetic Breast Reconstruction

EXPERIMENTAL
Procedure: Prepectoral Prosthetic Breast Reconstruction

Subpectoral Prosthetic Breast Reconstruction

ACTIVE COMPARATOR
Procedure: Subpectoral Prosthetic Breast Reconstruction

Interventions

The prepectoral approach involves placing the tissue expander on top of the pectoralis muscle.

Prepectoral Prosthetic Breast Reconstruction

The subpectoral approach involves placing the tissue expander under the pectoralis muscle with or without acellular dermal matrix (ADM).

Subpectoral Prosthetic Breast Reconstruction

Eligibility Criteria

Age21 Years - 60 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsBreast Reconstruction
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Women aged 21-60 years
  • Planning to undergo immediate two stage prosthetic breast reconstruction with TE placement as the first stage.
  • Planning to undergo unilateral or bilateral mastectomy.
  • Planning to undergo nipple- or skin-sparing mastectomy.
  • Mastectomy weight less than 800 grams.
  • Adequate mastectomy skin perfusion or patients with adequate perfusion but nonviable mastectomy skin that can be excised (≤ 4 cm) at the defect margins with otherwise adequate perfusion.

You may not qualify if:

  • Receipt of neoadjuvant chemotherapy for locally advanced breast cancer.
  • Presence of preoperative axillary lymph node metastasis.
  • Presence of intraoperative sentinel node positivity.
  • History of radiotherapy.
  • Current smoker.
  • Planning to undergo direct-to-implant reconstruction.
  • BMI \>35.
  • Prior sternotomy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Memorial Sloan Kettering BaskingRidge (Consent and Followup)

Basking Ridge, New Jersey, 07920, United States

Location

Memorial Sloan Kettering Monmouth (Consent and Followup)

Middletown, New Jersey, 07748, United States

Location

Memorial Sloan Kettering Bergen (Consent and Followup )

Montvale, New Jersey, 07645, United States

Location

Memorial Sloan Kettering Commack (Consent and Followup)

Commack, New York, 11725, United States

Location

Memorial Sloan Kettering Westchester (Consent and Followup)

Harrison, New York, 10604, United States

Location

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States

Location

Memorial Sloan Kettering Nassau (Consent and Followup)

Rockville Centre, New York, 11553, United States

Location

Related Links

Study Officials

  • Evan Matros, MD, MMSc, MPH

    Memorial Sloan Kettering Cancer Center

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 19, 2021

First Posted

January 20, 2021

Study Start

January 14, 2021

Primary Completion

December 13, 2021

Study Completion

December 13, 2021

Last Updated

January 3, 2022

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will share

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Locations